

Valentina Fanotto

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6924661/valentina-fanotto-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37
papers

705
citations

15
h-index

26
g-index

54
ext. papers

896
ext. citations

4.1
avg, IF

3.55
L-index

#	Paper	IF	Citations
37	Pattern of metastasis and outcome in patients with breast cancer. <i>Clinical and Experimental Metastasis</i> , 2015 , 32, 125-33	4.7	101
36	New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. <i>Frontiers in Pharmacology</i> , 2017 , 8, 354	5.6	96
35	Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 709-721	5.4	71
34	Gastric cancer: Translating novel concepts into clinical practice. <i>Cancer Treatment Reviews</i> , 2019 , 79, 101889	14.4	39
33	Molecular classifications of gastric cancers: Novel insights and possible future applications. <i>World Journal of Gastrointestinal Oncology</i> , 2017 , 9, 194-208	3.4	38
32	Do platinum salts fit all triple negative breast cancers?. <i>Cancer Treatment Reviews</i> , 2016 , 48, 34-41	14.4	38
31	The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019 , 10, 368-377	10.3	36
30	Sarcopenia in gastric cancer: when the loss costs too much. <i>Gastric Cancer</i> , 2017 , 20, 563-572	7.6	33
29	Immunotherapy for gastric cancers: emerging role and future perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 609-619	3.8	26
28	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017 , 20, 825-833	7.6	24
27	Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. <i>Clinical and Experimental Metastasis</i> , 2015 , 32, 819-33	4.7	24
26	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 365-374	5.4	23
25	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. <i>Oncotarget</i> , 2016 , 7, 69060-69074	3.3	21
24	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. <i>Cancers</i> , 2019 , 11,	6.6	17
23	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017 , 22, 1463-1469	5.7	17
22	Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. <i>Cancer Treatment Reviews</i> , 2019 , 72, 7-14	14.4	12
21	Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer. <i>Infectious Agents and Cancer</i> , 2020 , 15, 42	3.5	10

20	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018 , 95, 344-352	3.6	9
19	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017 , 13, 2265-2275	3.6	8
18	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. <i>Scientific Reports</i> , 2020 , 10, 7010	4.9	8
17	Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study. <i>Clinical Nutrition</i> , 2021 , 40, 286-294	5.9	8
16	Determinants of Last-line Treatment in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018 , 18, 205-213	3.3	7
15	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020 , 25, 661-668	5.7	6
14	Pattern of metastatic spread and prognosis of breast cancer biologic subtypes.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e12532-e12532	2.2	6
13	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. <i>Breast</i> , 2018 , 40, 45-52	3.6	4
12	FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial. <i>Annals of Oncology</i> , 2016 , 27, vi560	10.3	4
11	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 591-597	3.6	4
10	Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e13079-e13079	2.2	2
9	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. <i>Future Oncology</i> , 2020 , 16, 2059-2073	3.6	1
8	A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring. <i>PLoS ONE</i> , 2021 , 16, e0259137	3.7	0
7	LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16102-e16102	2.2	0
6	New Agents in the Treatment of Advanced Gastric Cancer: Targeted Therapy and Immunotherapy. <i>Current Clinical Pathology</i> , 2019 , 121-132	0.1	
5	Serum Biomarkers in Gastric Cancer. <i>Current Clinical Pathology</i> , 2019 , 107-117	0.1	
4	Treatment during the last month of life in advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17649-e17649	2.2	
3	Prognostic factors in 868 advanced gastric cancer patients exposed to second-line therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15553-e15553	2.2	

- 2 Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.. *Journal of Clinical Oncology*, **2017**, 35, e12010-e12010 2.2
- 1 Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncologyPhysicians inform oncological patients.. *Journal of Clinical Oncology*, **2017**, 35, e21632-e21632 2.2